Abstract:ABSTRACT Hepatitis C virus (HCV) entry involves binding to cell surface heparan sulfate (HS) structures. However, due to the lipoprotein-like structure of HCV, the exact contribution of virion components to this interaction remains controversial. Here, we investigated the relative contribution of HCV envelope proteins and apolipoprotein E in the HS-binding step. Deletion of hypervariable region 1, a region previously proposed to be involved in HS binding, did not alter HCV virion binding to HS, indicating that this region is not involved in this interaction in the context of a viral infection. Patient sera and monoclonal antibodies recognizing different regions of HCV envelope glycoproteins were also used in a pulldown assay with beads coated with heparin, a close HS structural homologue. Although isolated HCV envelope glycoproteins could interact with heparin, none of these antibodies was able to interfere with the virion-heparin interaction, strongly suggesting that at the virion surface, HCV envelope glycoproteins are not accessible for HS binding. In contrast, results from kinetic studies, heparin pulldown experiments, and inhibition experiments with anti-apolipoprotein E antibodies indicated that this apolipoprotein plays a major role in HCV-HS interaction. Finally, characterization of the HS structural determinants required for HCV infection by silencing of the enzymes involved in the HS biosynthesis pathway and by competition with modified heparin indicated that N- and 6-O-sulfation but not 2-O-sulfation is required for HCV infection and that the minimum HS oligosaccharide length required for HCV infection is a decasaccharide. Together, these data indicate that HCV hijacks apolipoprotein E to initiate its interaction with specific HS structures. IMPORTANCE Hepatitis C is a global health problem. Hepatitis C virus (HCV) infects approximately 130 million individuals worldwide, with the majority of cases remaining undiagnosed and untreated. In most infected individuals, the virus evades the immune system and establishes a chronic infection. As a consequence, hepatitis C is the leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and liver transplantation. Virus infection is initiated by entry of the virus into the host cell. In this study, we provide new insights into the viral and cellular determinants involved in the first step of HCV entry, the binding of the virus to host cells. We show that apolipoprotein E is likely responsible for virus binding to heparan sulfate and that N- and 6-O-sulfation of the heparan sulfate proteoglycans is required for HCV infection. In addition, the minimal HS length unit required for HCV infection is a decasaccharide.

ApoE3 blocks HCV entry inhibitor ficolin-2 (INM8P.437)

A human claudin-1-derived peptide inhibits hepatitis C virus entry

Human L-ficolin Can Bind and Defence Against Multiple Pathogens (89.29)

Hepatitis C Virus Attachment Mediated by Apolipoprotein E Binding to Cell Surface Heparan Sulfate

Apolipoprotein E Interacts with Hepatitis C Virus Nonstructural Protein 5A and Determines Assembly of Infectious Particles.

Apolipoprotein E Mediates Attachment of Clinical Hepatitis C Virus to Hepatocytes by Binding to Cell Surface Heparan Sulfate Proteoglycan Receptors

A novel small molecule inhibitor of hepatitis C virus entry

Identification of Interferon Receptor IFNAR2 As a Novel HCV Entry Factor by Using Chemical Probes

Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases

Human Apolipoprotein E is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture.

Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition

Roles of human apolipoprotein E in the infectivity and replication of hepatitis C virus genotype 2a

The C-terminal α-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus

Host Apolipoprotein B Messenger RNA-editing Enzyme Catalytic Polypeptide-Like 3G is an Innate Defensive Factor and Drug Target Against Hepatitis C Virus

Apolipoprotein M, identified as a novel hepatitis C virus (HCV) particle associated protein, contributes to HCV assembly and interacts with E2 protein

Characterization of Apolipoprotein C1 in Hepatitis C Virus Infection and Morphogenesis.

Species-specific regions of occludin required by hepatitis C virus for cell entry

Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection

Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions.

Claudin-6 and Claudin-9 Function As Additional Coreceptors for Hepatitis C Virus

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans